Journal
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 13, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758835920986518
Keywords
gastric cancer; HER2; T-DXd; trastuzumab deruxtecan
Categories
Funding
- Taiho Pharmaceutical
- Astellas Pharma
- Ono Pharmaceutical
- Eli Lilly and Company
- Merck Pharmaceutical
Ask authors/readers for more resources
Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate for HER2-positive gastric cancer, showing potential anti-tumor activities in preclinical and clinical studies. In a phase II trial, T-DXd demonstrated higher objective response rate and longer overall survival in patients with pretreated HER2-positive advanced gastric cancer.
Trastuzumab deruxtecan (T-DXd) is a novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, DX-8951 derivative (an exatecan derivative). T-DXd showed potential anti-tumor activities in HER2-positive gastric cancer cell lines and xenograft models. In the randomized, phase II trial DESTINY-Gastric01, T-DXd demonstrated a significantly higher objective response rate as a primary endpoint and a longer overall survival as a secondary endpoint in patients with pretreated HER2-positive advanced gastric cancer (AGC). Although adverse events caused by T-DXd were generally manageable, approximately 10% of patients experienced treatment-related interstitial lung disease. Based on the results of the DESTINY-Gastric01 trial, T-DXd was approved for HER2-positive pretreated AGC in Japan. This study reviews the preclinical and clinical data of T-DXd for treating HER2-positive gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available